



Cytomegalovirus (CMV) Infection and Latency

Guest Editor:

Dr. Christine M. O'Connor

Genomic Medicine, Lerner
Research Institute, Cleveland
Clinic, Cleveland, OH 44106, USA

Deadline for manuscript
submissions:

closed (31 January 2021)

Message from the Guest Editor

Cytomegalovirus (CMV) is a herpesvirus that infects the majority of the population worldwide. While latent infection remains, for the most part, asymptomatic in healthy, immune-competent individuals, the virus poses a significant threat to those with weakened immune systems. CMV-associated disease following reactivation of latent infection is a risk factor for transplant patients undergoing immunosuppressive therapies, cancer patients treated with aggressive chemotherapies, immunocompromised AIDS patients, and even otherwise healthy individuals suffering from diseases such as atherosclerosis and inflammatory bowel disease. The current antiviral therapies target late stages of viral replication, when the disease is already primed to occur, underscoring the need for novel treatments targeting CMV prior to disease onset. This necessitates enhanced understanding of the latent and reactivation phases of infection.

Continued efforts aimed at understanding CMV latency and reactivation will undoubtedly provide insights into the mechanisms this pathogen uses to manipulate its host and cause disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](#)